查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433659

美国次要大麻素市场规模、份额和趋势分析报告：按产品类型、应用和细分市场预测，2024-2030 年

U.S. Minor Cannabinoids Market Size, Share & Trends Analysis Report By Product (Cannabigerol (CBG), Tetrahydrocannabivarin (THCV), Cannabichromene (CBC)), By Application (Cancer, Inflammation, Neurological Disorders),& Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国次要大麻素市场成长与趋势：

Grand View Research 的一项新研究显示，到 2030 年，美国次要大麻素市场预计将达到 333 亿美元。

预计2024年至2030年该市场将以15.0%的复合年增长率扩张。大麻素产品的使用不断增加以及人们对大麻素消费带来的健康益处的认识是支持成长的一些关键因素。

次要大麻素具有潜在的治疗作用，包括发炎、镇痛和神经保护作用。人们越来越有兴趣开发含有少量大麻素的食品和营养补充，用于治疗慢性疼痛、焦虑和睡眠障碍等各种疾病。例如，2021 年 1 月，Lygos, Inc. 宣布大麻环烯 (CBC) 的商业用途，它具有广泛的益处，包括发炎、抗氧化和疼痛管理特性。

补充品、酊剂和外用药等保健产品均含有少量大麻素。这些产品作为治疗各种健康问题的自然疗法进行销售，并在寻求传统药物替代品的消费者中越来越受欢迎。例如，个人护理和健康保健产品供应商Nextraction提供其Kriva系列外用製剂，其中含有大麻酚(CBN)、大麻二酚酸(CBDA)和大麻二酚酸(CBGA)，并以可摄入的製剂形式释放。

主要企业为加强其在美国次要大麻素行业的商机和足迹而进行的各种有机和无机开发预计将在预测期内推动市场扩张。 2022 年 10 月，生技公司 Purissima, Inc. 与 Open Book Extracts (OBX) 合作推出了首款发酵衍生的天然 CBC 产品，包括软糖、外用精华液、酊剂和胶囊。

美国次要大麻素市场报告亮点：

  • 按产品类型划分，四氢大麻酚 (THCV) 细分市场占据主导地位，2023 年销售份额为 25.9%。这是由于 THCV 在治疗关节炎、代谢失调和癫痫等疾病方面的应用越来越多。
  • 按应用来看，由于神经系统疾病盛行率不断上升以及大麻素在其治疗中的应用，神经系统疾病细分市场在 2023 年将占据重要的收益占有率。
  • 主要市场参与者：GCM Holdings (Global Cannabinoids), LLC、GenCanna、Mile High Labs、ZERO POINT EXTRACTION, LLC、BulKanna、CBD.INC。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章美国次要大麻素市场：变数、趋势、范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国次要大麻素市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国小规模大麻素市场：产品类型估算与趋势分析

  • 2023 年及 2030 年产品类型市场占有率
  • 细分仪表板
  • 按产品类型分類的美国次要大麻素市场前景
  • 2018年至2030年市场规模、预测与趋势分析

第五章美国次要大麻素市场：使用量估计与趋势分析

  • 2023年及2030年应用市场占有率
  • 细分仪表板
  • 美国次要大麻素市场前景（按应用）
  • 2018年至2030年市场规模、预测与趋势分析

第六章 竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • Mile High Labs
    • GCM Holdings, LLC
    • GenCanna.
    • CBD. INC.
    • Rhizo Sciences
    • Laurelcrest
    • Fresh Bros Hemp Company
    • BulKanna
    • High Purity Natural Products
    • ZERO POINT EXTRACTION, LLC
Product Code: GVR-4-68039-683-5

U.S. Minor Cannabinoids Market Growth & Trends:

The U.S. minor cannabinoids market size is expected to reach USD 33.3 billion by 2030, according to a new study by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.0% from 2024 to 2030. Rising use of cannabinoid-based products and awareness regarding the health benefits associated with cannabinoid consumption are some of the crucial factors supporting the growth.

Minor cannabinoids have potential therapeutic benefits, including anti-inflammatory, analgesic, and neuroprotective effects. There is a growing interest in developing pharmaceuticals and nutraceuticals containing minor cannabinoids for the treatment of various medical conditions, such as chronic pain, anxiety, and sleep disorders. For instance, in January 2021, Lygos, Inc. announced the commercial availability of cannabichromene (CBC) that has a wide range of anti-inflammatory, antioxidant, and pain management properties.

Wellness products such as supplements, tinctures, and topicals incorporate minor cannabinoids. These products are marketed as natural remedies for various health issues, and are becoming popular among consumers who are looking for alternatives to traditional medications. For instance, Nextraction, a supplier of personal care and health & wellness products, launched Kriva-a range of Cannabinol (CBN), cannabidiol acid (CBDA), and Cannabigerolic acid (CBGA)-in topical and ingestible formulas.

Various organic and inorganic developments done by key players to strengthen their business avenues and footprints in the U.S. minor cannabinoids industry are anticipated to facilitate market expansion over the forecast period. In October 2022, Purissima, Inc., a biotechnology company in partnership with Open Book Extracts (OBX), launched its first fermentation-derived natural CBC products such as gummies, topical serums, tinctures, and capsules.

U.S. Minor Cannabinoids Market Report Highlights:

  • Based on product type, the tetrahydrocannabivarin (THCV) segment dominated the market with a revenue share of 25.9% in 2023, owing to increasing application of THCV in the management of conditions such as arthritis, metabolic disorders, and epilepsy
  • Based on application, the neurological disorders segment accounted for a significant revenue share in 2023, due to the rising prevalence of neurological disorders and applications of cannabinoids in their management
  • Some of the major market players include GCM Holdings (Global Cannabinoids), LLC, GenCanna, Mile High Labs, ZERO POINT EXTRACTION, LLC, BulKanna, and CBD. INC.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Type
    • 1.2.2. Application
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product type outlook
    • 2.2.2. Application outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Minor Cannabinoids Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Minor Cannabinoids Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Minor Cannabinoids Market: Product Type Estimates & Trend Analysis

  • 4.1. Product Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Minor Cannabinoids Market by Product Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Cannabigerol (CBG)
      • 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Cannabichromene (CBC)
      • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Cannabinol (CBN)
      • 4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Tetrahydrocannabivarin (THCV)
      • 4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Cannabigerolic acid (CBGA)
      • 4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Minor Cannabinoids Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global U.S. Minor Cannabinoids Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Inflammation
      • 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. Pain Management
      • 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. Neurological Disorders
      • 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.4. Cancer
      • 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. Mile High Labs
      • 6.3.1.1. Company overview
      • 6.3.1.2. Financial performance
      • 6.3.1.3. Product benchmarking
      • 6.3.1.4. Strategic initiatives
    • 6.3.2. GCM Holdings, LLC
      • 6.3.2.1. Company overview
      • 6.3.2.2. Financial performance
      • 6.3.2.3. Product benchmarking
      • 6.3.2.4. Strategic initiatives
    • 6.3.3. GenCanna.
      • 6.3.3.1. Company overview
      • 6.3.3.2. Financial performance
      • 6.3.3.3. Product benchmarking
      • 6.3.3.4. Strategic initiatives
    • 6.3.4. CBD. INC.
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Rhizo Sciences
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. Laurelcrest
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Fresh Bros Hemp Company
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. BulKanna
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. High Purity Natural Products
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Product benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. ZERO POINT EXTRACTION, LLC
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Product benchmarking
      • 6.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. minor cannabinoids market, by product type, 2018 - 2030 (USD Million)
  • Table 3 U.S. minor cannabinoids market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. minor cannabinoids market: market outlook
  • Fig. 9 U.S. minor cannabinoids competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 U.S. minor cannabinoids market driver impact
  • Fig. 15 U.S. minor cannabinoids market restraint impact
  • Fig. 16 U.S. minor cannabinoids market strategic initiatives analysis
  • Fig. 17 U.S. minor cannabinoids market: Product type movement analysis
  • Fig. 18 U.S. minor cannabinoids market: Product type outlook and key takeaways
  • Fig. 19 Cannabigerol (CBG)market estimates and forecast, 2018 - 2030
  • Fig. 20 Cannabichromene (CBC) market estimates and forecast, 2018 - 2030
  • Fig. 21 Cannabinol (CBN) market estimates market and forecast, 2018 - 2030
  • Fig. 22 Tetrahydrocannabivarin (THCV) market estimates and forecast, 2018 - 2030
  • Fig. 23 Cannabigerolic acid (CBGA) market estimates and forecast, 2018 - 2030
  • Fig. 24 Others (Cannabidiolic Acid (CBDA), Cannabidivarin (CBDV), And Other Minor Cannabinoids) estimates and forecast, 2018 - 2030
  • Fig. 25 U.S. minor cannabinoids market: Application movement Analysis
  • Fig. 26 U.S. minor cannabinoids market: Application outlook and key takeaways
  • Fig. 27 Inflammation market estimates and forecasts, 2018 - 2030
  • Fig. 28 Pain management market estimates and forecasts, 2018 - 2030
  • Fig. 29 Neurological disorders market estimates and forecasts,2 018 - 2030
  • Fig. 30 Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 31 Others market estimates and forecasts, 2018 - 2030